Markets | |
One of the biggest components of successful trading is the ability to understand current market conditions. Many new traders learn the hard way that trying to force trades in a market without direction can be a quick way to lose money. Sometimes, the most prudent thing to do as a trader is to do n... Read the Full Story |
|
From Our Partners | | Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge.
Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks.
Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | | Watch Marc Chaikin's free presentation and get his full buy-and-sell list today |
|
Markets | | Payment solutions provider Square (NYSE: SQ) shares took a heavy bearing during the coronavirus pandemic sinking to lows of $32.33 on March 18, 2020. This move was positively correlated to the S&P 500 (NYSEARCA: SPY) which collapsed over 35 percent in just under a month. Prior to this black swan... Read the Full Story |
|
Markets | |
Have we turned a corner? This inherently hopeful and largely rhetorical question has underscored a lot of the world's life these days. Has the coronavirus pandemic started retreating to the point where life looks like it once did and we can actually go back to work? Has the stock market stopped it... Read the Full Story |
|
From Our Partners | | TradeSmith CEO Keith Kaplan warns that AI's rapid rise has a dark side, threatening American jobs and livelihoods. He says now is the time to prepare before August 31st.
TradeSmith has invested $17 million in AI tools and built a platform used by 180,000 traders worldwide. One user, Stephen, credits it with building a $2.95 million retirement portfolio. | | See where Kaplan says to move your money before August 31st |
|
Markets | | As markets continue to rebound from one of the most vicious sell-offs in history, many investors are looking for quality stocks that are trading at significant discounts to where they were a month or two ago. While overall volatility is still elevated, there’s no doubt that attractive buying o... Read the Full Story |
|
Markets | | A Preemptive Strike
When the market saw the black swan of coronavirus approaching it reacted in the only way it could. Instead of waiting for this thing to hit, waiting to see how bad it might be, the market started selling. The general thought went something like this “it’s better to b... Read the Full Story |
|
From Our Partners | | Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | | Discover the gold income fund before the next payout date |
|
Markets | | The equity markets have seen unprecedented volatility in 2020 triggered by the COVID-19 pandemic black swan event. The S&P 500 ETF (NYSEARCA: SPY) has broken all kinds of records including the fastest drop into a bear market in history collapsing in excess of (-30 percent) from highs in just thr... Read the Full Story |
|
Markets | | Even as the major indices have been setting records for intra-day and intra-week swings and volatility reaches never before seen heights, there are some stocks, who by their mechanics, are destined to move even faster. Welcome to the world of 2x and 3x ETFs. These guys use debt and or derivatives to... Read the Full Story |
|
Markets | | The storied history of Bitcoin (BTC) reveals how the very first block aptly referred to as the Genesis Block, was mined by its anonymous creator Satoshi Nakamoto on January 3, 2009. On that Genesis Block was the inscription, “The Times 03/Jan/2009 Chancellor on bringing of the second bailout f... Read the Full Story |
|
Markets | | Sell The Rumor, Buy The News
JonesTrading Chief Market Strategies Mike O’Rourke says we are on the brink of Bear-Maggedon. Bear-Maggedon, to him, is the toxic-combination economic-rollover in the face of easy money policy. In this environment, investors will begin to fear the Fed’s abil... Read the Full Story |
|
Markets | |
Sometimes, when market volatility is on the rise, finding places that can protect your money and avoid downside risk is huge. One of the crucial things to understand about investing is that risk is always a possibility. If you look at the recent volatility in the market, you might be wondering whe... Read the Full Story |
|
The Early Bird Stock Of The Day Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada. | | View Today's Stock Pick |
|
